论文部分内容阅读
目的探讨替吉奥与单药氟尿嘧啶加同步放疗治疗中晚期食管癌的近期临床疗效。方法将66例中晚期食管癌患者随机分为两组,替吉奥胶囊口服+同步放疗组(试验组)38例,单药氟尿嘧啶静点+同步放疗组(对照组)28例,放疗方案均采用食管病灶区适形调强放射治疗(intensity modulated radiation therapy),放疗剂量为60~66Gy。观察两组临床疗效、生存情况及毒副反应。结果试验组和对照组的治疗有效率分别为89.4%和89.3%,差异无统计学意义(χ2=0.012,P=0.996);两组的1年、2年生存率分别为86.1%、64.1%和76.9%、41.9%,差异无统计学意义;两组总的生存率比较差异无统计学意义(χ2=0.755,P=0.097);两组均无严重的放射性食管炎(3~4级)及血液学毒副反应(Ⅳ°)的发生。结论替吉奥联合放射治疗中晚期食管癌有较好的近期疗效,且毒副反应可耐受。
Objective To explore the short-term clinical efficacy of tegaserod and single-agent fluorouracil plus concurrent radiotherapy in the treatment of advanced esophageal cancer. Methods Sixty-six patients with advanced esophageal cancer were randomly divided into two groups: 38 cases in the group of Teglitazone oral + synchronous radiotherapy (experimental group), 28 cases in the single fluorouracil static group (control group) and 28 cases in the radiotherapy group The use of intensity modulated radiation therapy in esophageal lesions, radiation dose of 60 ~ 66Gy. The clinical efficacy, survival and toxicity of the two groups were observed. Results The effective rates of treatment group and control group were 89.4% and 89.3% respectively, with no significant difference (χ2 = 0.012, P = 0.996). The 1-year and 2-year survival rates of the two groups were 86.1% and 64.1% And 76.9%, 41.9% respectively. There was no significant difference between the two groups (χ2 = 0.755, P = 0.097). There was no serious radiation esophagitis (grade 3-4) And hematological toxicities (Ⅳ °) occurred. Conclusion For the treatment of advanced esophageal cancer with Gioia combined radiotherapy has a good short-term efficacy, and toxicity can be tolerated.